Creative Medical Technology Announces Top-Line Results For StemSpine Pilot Study; Says 'There Were No Safety Related Concerns At Up To Two Years And The StemSpine Procedure Resulted In An Efficacy Rate Of 87% In The Treated Patients'
Creative Medical Technology Announces Top-Line Results For StemSpine Pilot Study; Says 'There Were No Safety Related Concerns At Up To Two Years And The StemSpine Procedure Resulted In An Efficacy Rate Of 87% In The Treated Patients'
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ:CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced positive two-year follow-up data for the Company's StemSpine® pilot study, showing significant efficacy of the StemSpine® procedure for treating chronic lower back pain without any serious adverse effects reported.
亚洲网加利福尼亚州圣何塞10月23日电专注于免疫疗法、泌尿外科、神经病学和整形外科再生疗法的领先商业期生物技术公司Creative Medical Technology Holdings，Inc.(以下简称“创意医疗科技”或“公司”)(纳斯达克代码：CELZ)今天宣布，该公司的StemSpine®试点研究的两年随访数据显示，StemSpine®疗法在治疗慢性下腰痛方面显著有效，且未报告任何严重不良反应。
StemSpine® is a patented procedure that utilizes a patient's own bone marrow aspirate for the treatment of chronic lower back pain.
StemSpine®是一种专利手术，它利用患者自己的骨髓抽吸物治疗慢性下腰痛。
There were no safety related concerns at up to two years and the StemSpine® procedure resulted in an efficacy rate of 87% in the treated patients. The Company plans to submit a manuscript for publication in a peer reviewed journal and present the data at future orthopedic/sports medicine conferences.
在长达两年的时间里，没有安全相关的问题，StemSpine®程序在接受治疗的患者中产生了87%的有效率。该公司计划提交一份手稿，在同行评议的期刊上发表，并在未来的整形外科/运动医学会议上展示数据。
"The positive two-year data from our StemSpine® pilot study are very encouraging, and we are excited to engage with practitioners on commercialization," said Timothy Warbington, President and CEO of the Company. "To our knowledge, this pilot is the first demonstration of the clinical efficacy of injecting bone marrow aspirate in areas surrounding the disc, thereby repairing, remodeling and improving the blood supply around the disc and lower back area. We believe StemSpine® represents an attractive non-surgical option for many of the millions of Americans who suffer from non-surgical chronic lower back pain."
该公司总裁兼首席执行官蒂莫西·沃宾顿说：“我们StemSpine®试点研究的两年来的积极数据非常令人鼓舞，我们很高兴能与实践者就商业化问题进行接触。据我们所知，这项试验首次展示了在腰椎间盘周围区域注射骨髓抽吸物的临床疗效，从而修复、重塑和改善腰椎间盘和下背部区域的血液供应。我们相信，对于数百万患有非手术慢性下腰痛的美国人来说，StemSpine®是一个有吸引力的非手术选择。
Sahil Nock, Chief Commercialization Officer of the Company, added, "Given our timely receipt of this significant and favorable data, I look forward to accelerating our StemSpine® program by introduction to the physician community at the American Academy of Orthopaedic Surgeons annual conference taking place in Chicago this week, March 22-26. Building out strong advisory boards with notable KOLs has been a pillar of my career and I am excited to leverage my experience to accelerate our efforts to translate the StemSpine® procedure."
该公司首席商业化官Sahil Nock补充说：“鉴于我们及时收到了这些重要和有利的数据，我期待着通过在本周(3月22-26日)在芝加哥举行的美国整形外科学会年会上向医生群体介绍StemSpine®计划来加快我们的StemSpine®计划。通过著名的KOL建立强大的顾问委员会一直是我职业生涯的支柱，我很高兴能利用我的经验加快我们翻译StemSpine®程序的努力。”
The Company plans to hold a series of 1:1 meetings with physicians throughout the conference. Please contact Sahil Nock utilizing information found at the end of this press release if you would like to connect. We may also be contacted through our website at .
该公司计划在整个会议期间与医生举行一系列1：1的会议。如果您想联系，请使用本新闻稿末尾的信息联系Sahil Nock。我们也可以通过我们的网站联系我们。